

Company Update June 26, 2015

# **Torrent Pharmaceuticals Ltd.**

Multiple drivers in place for higher growth going forward

Current	Previous
CMP : Rs.1,345	
Rating : BUY	Rating : HOLD
Target : Rs.1,599	Target : Rs.1,190

STOCK INFO	
BSE	500420
NSE	TORNTPHARM
Index	S&P BSE 200
Bloomberg	TRP IN
Reuters	TORP.BO
Sector	Pharmaceutical
Face Value (Rs)	5
Equity Capital (Rs mn)	846
Mkt Cap (Rs mn)	227,458
52w H/L(Rs)	1,369 / 656
Avg Daily Vol (BSE+NSE)	260,568
SHAREHOLDING PATTERN	%
(as on Mar. 2015)	
Promoters	71.2


Public & Others

FIIs

DIIs

Source: BSE

<b>STOCK PERFORMANCE (%)</b>	1m	3m	12m				
TORRENT PHARMA	8.4	18.5	91.4				
SENSEX	1.3	1.6	11.3				
Source: Capitaline. IndiaNivesh Research							



# Daljeet S. Kohli

Head of Research

Tel: +91 22 66188826 daljeet.kohli@indianivesh.in

Tushar Manudhane Research Analyst

Tel: +91 22 66188835 tushar.manudhane@indianivesh.in We expect Torrent Pharmaceuticals (TRP) to have sales of US\$130mn for FY16E from g-Abilify opportunity. Given the market size of Abilify to be ~US\$5bn on annual basis, at-risk launch and one among the few early entrants for generic version of Abilify in US market, we expect TRP to have considerable traction from this product. Accordingly, we raise our EPS estimate by 28.9% and 28% to Rs70.5 and Rs76.1 for FY16E and FY17E, respectively. We also raise PE multiple from 20x to 22x to factor robust ANDA pipeline, increased capacity post commissioning of Dahej facility, product diversification expected to be achieved in regulated markets through acquisition of Zyg Pharma and ongoing revival of Elder portfolio. We raise our price target from Rs1,190 to Rs1,599 based on FY17E earnings. With 18.9% upside from current levels, we upgrade TRP from HOLD to BUY. At CMP of Rs1,345, the stock is trading at 19.1x FY16E EPS of Rs70.5 and 17.7x FY17E EPS of Rs76.1.

# Key changes in estimates

Rs mn	Old estimates		New esti	mates	Change (%)	
RS IIII	FY16E	FY17E	FY16E	FY17E	FY16E	FY17E
Sales	56,190	64,185	64,250	70,224	14.3	9.4
EBITDA	13,764	15,962	17,146	18,529	24.6	16.1
PAT	9,258	10,069	11,929	12,887	28.9	28.0
EPS (Rs)	54.7	59.5	70.5	76.1	28.9	28.0
PT (Rs)		1,190		1,599		

Source: IndiaNivesh Research

12.3

6.8

9.7

# G-Abilify case background:

Ostuka Pharmaceutical Co. (Otsuka) had sued Alembic Pharma (ALPM), Torrent Pharma (TRP), Teva, Hetero Drugs, Sun Pharmaceuticals, Sandoz and Apotex for para IV filing of g-Abilify. While the litigation with companies for generic version was ongoing, Otsuka was simultaneously trying to get marketing exclusivity for seven years under Orphan drug act on account of treating Tourette's syndrome for orphans. However, USFDA approved first generic version of Abilify to treat schizophrenia and bipolar disorder. USFDA approved the generic version of Abilify on 20 April 2015 when the period of pediatric exclusivity associated with US patent no: 5,006,528 expired. Also, the innovator lost the lawsuit challenging FDA approval of generic Abilify in US district court in May 2015. Based on the FDA approval and outcome in US district court, ALPM, TRP, Teva and Hetero launched g-Abilify at risk in US market. The Otsuka's attempt to go to higher court to prevent generics and having the verdict in its favor is the key risk for "At-risk" launch by generic players.

# **Potential business for Torrent Pharma:**

Media sources indicate 11% market share garnered by TRP in a month post launch. We expect gradual gain in market share as well as price stability as long as entry of new players is delayed. The innovator had annual sales of about ~US\$5bn for 12-months ending March 2015. With limited competition for this product, we expect TRP to have sales of ~US\$130mn for FY16 on the back of 10-12% market share and 30-40% price erosion. If the entry of new players is earlier than expected then the sales from this opportunity could be US\$100mn (bear case scenario) on the back of price erosion and loss of market share to some extent. Given the product size and delay in entry of players could mean sales of US\$300mn for TRP (bull case scenario).

# Valuation:

We increase our EPS estimate by 28.9% and 28% to Rs70.5 and Rs76.1 for FY16E and FY17E, respectively. We raise PE multiple from 20x to 22x to factor robust ANDA pipeline, increased capacity post commissioning of Dahej facility, product diversification expected to be achieved in regulated markets through acquisition of Zyg Pharma and ongoing revival of Elder portfolio. Accordingly, we raise our price

IndiaNivesh Securities Private Limited | Research Analyst SEBI Registration No. INH000000511 601 & 602, Sukh Sagar, N. S. Patkar Marg, Girgaum Chowpatty, Mumbai 400 007. Tel: (022) 66188800

IndiaNivesh Research is also available on Bloomberg INNS, Thomson First Call, Reuters and Factiva INDNIV.

IndiaNivesh Research

target from Rs1,190 to Rs1,599 based on 22x FY17E earnings. With 18.9% upside from current levels, we upgrade TRP from HOLD to BUY. At CMP of Rs1,345, the stock is trading at 19.1x FY16E EPS of Rs70.5 and 17.7x FY17E EPS of Rs76.1.

### Key risks:

Otsuka's attempt to go to higher court and getting verdict in its favor, earlier-thanexpected entry of new players in g-Abilify market, delay in ANDA approvals and delay in revival of Elder portfolio are the key risks to our price target and rating for TRP.

# **Finanical Summary**

Profit & Loss					
Y E March (Rs m)	FY13	FY14	FY15AE	FY16E	FY17E
Net sales	30,540	40,360	45,850	64,250	70,224
Growth %	17.7%	32.2%	13.6%	40.1%	9.3%
Other Operating Income	1,580	1,480	680	1,072	1,119
Total sales	32,120	41,840	46,530	65,322	71,343
Expenditure					
Raw Material	9,260	12,430	14,150	20,399	21,067
Employee cost	6,230	7,410	8,420	10,525	11,827
Other expenses	9,700	12,480	13,760	17,252	19,919
EBITDA	6,930	9,520	10,200	17,146	18,529
Growth %	38.4%	37.4%	7.1%	68.1%	8.1%
EBITDA Margin %	17.5%	19.9%	20.8%	25.0%	24.8%
Depreciation	830	870	1,910	1,995	2,102
EBIT	6,100	8,650	8,290	15,150	16,427
EBIT Margin %	20.0%	21.4%	18.1%	23.6%	23.4%
Other Income	430	380	2,860	1,800	1,500
Interest	340	590	1,750	1,850	1,615
PBT	6,190	8,440	9,400	15,100	16,312
Tax	1,470	1,800	1,890	3,171	3,426
Effective tax rate %	23.7%	21.3%	20.1%	21.0%	21.0%
Extraordinary items	(370)	-	-	-	-
Minority Interest	(20)	-	-	-	-
Adjusted PAT	4,700	6,640	7,510	11,929	12,887
Growth%	34.5%	41.3%	13.1%	58.8%	8.0%
PAT margin %	15.4%	16.5%	16.4%	18.6%	18.4%
Reported PAT	4,330	6,640	7,510	11,929	12,887
Growth%	52.4%	53.3%	13.1%	58.8%	8.0%

Cash Flow					
Y E March (Rs m)	FY13	FY14	FY15AE	FY16E	FY17E
РВТ	5,820	8,440	6,494	15,100	16,312
Depreciation	827	870	1,910	1,995	2,102
Interest	-	312	1,750	1,850	1,615
Other non cash charges	430	186	-	-	-
Changes in working capital	(4,218)	(1,197)	(6,738)	2,869	(718)
Тах	(1,325)	(2,617)	(1,249)	(3,171)	(3,426)
Cash flow fromoperations	1,535	5,994	2,167	18,643	15,886
Capital expenditure	(2,929)	(4,001)	(25,400)	(4,497)	(4,213)
Free Cash Flow	(1,394)	1,994	(23,232)	14,146	11,672
Other income	425	337	-	-	-
Investments	87	106	700	-	-
Cash flow from investments	(2,417)	(3,558)	(24,700)	(4,497)	(4,213)
Equity capital raised	-	-	-	-	-
Loans availed or (repaid)	1,343	4,149	21,486	(2,000)	(2,000)
Interest paid	(312)	(610)	(1,750)	(1,850)	(1,615)
Dividend paid (incl tax)	(834)	(2,674)	(1,083)	(2,360)	(2,653)
Cash flow from Financing	197	865	18,653	(6,210)	(6,268)
Net change in cash	(685)	3,301	(3,880)	7,935	5,404
Cash at the beginning of the year	7,608	6,270	9,550	5,671	13,606
Foreign currency exchange impact	(49)	(624)	-	-	-
Cash at the end of the year	6,270	7,694	5,671	13,606	19,010
Source: Company Filings; IndiaNivesh Research					

Balance sheet					
Y E March (Rs m)	FY13	FY14	FY15AE	FY16E	FY17E
Change Caraltal	122	046	046	0.46	0.45
Share Capital	423	846	846	846	846
Reserves & Surplus	13,796	18,178	24,060	33,629	43,862
Net Worth	14,219	19,024	24,906	34,475	44,709
Minority Interest	4	4	4	4	4
Secured Loans	5,474	8,890	30,376	28,376	26,376
Unsecured Loans	1,587	2,464	2,464	2,464	2,464
Total debt	7,061	11,354	32,840	30,840	28,840
Net defered tax liability	258	(182)	1,050	1,050	1,050
Total Liabilities	21,542	30,201	58,801	66,369	74,603
Gross Block	12,955	14,200	38,900	43,397	47,611
Less: Depreciation	4,757	5,447	7,357	9,352	11,454
Net Block	8,198	8,753	32,243	34,745	36,857
Capital Work in Progress	3,273	6,177	6,057	6,057	6,057
Investments	844	2,464	2,980	2,980	2,980
Current Assets					
Inventories	9,239	10,060	10,670	18,483	20,201
Sundry Debtors	6,878	10,994	15,950	14,434	15,776
Cash & Bank Balance	6,270	7,694	5,671	13,606	19,010
Other Current Assets	1,859	2,590	4,730	4,730	4,730
Loans & advances	968	1,209	3,160	1,584	1,732
	25,213	32,547	40,181	52,837	61,450
Current Liabilities & provisions	-				
Current Liabilities	12,266	16,202	18,280	25,870	28,360
Provisions	3,720	3,538	4,380	4,380	4,380
	15,986	19,740	22,660	30,250	32,740
Net Current Assets	9,227	12,807	17,521	22,587	28,709
Total assets	21,542	30,201	58,801	66,369	74,603
· · · · · · · · · ·					
Key ratios	_				
Y E March	FY13	FY14	FY15AE	FY16E	FY17E
EDC (Dc)	25.6	20.2	11 1	70 E	76 1

Key ratios					
Y E March	FY13	FY14	FY15AE	FY16E	FY17E
EPS (Rs)	25.6	39.2	44.4	70.5	76.1
Cash EPS (Rs)	30.5	44.4	55.7	82.3	88.6
DPS (Rs)	11.5	10.0	5.5	12.0	13.5
BVPS	84.0	112.4	147.2	203.7	264.2
ROCE	13.4%	16.9%	8.6%	15.5%	15.2%
ROE	30.5%	34.9%	30.2%	34.6%	28.8%
EBITDA Margin %	17.5%	19.9%	20.8%	25.0%	24.8%
Net Margin %	15.4%	16.5%	16.4%	18.6%	18.4%
PER (x)	52.6	34.3	30.3	19.1	17.7
P/BV (x)	16.0	12.0	9.1	6.6	5.1
P/CEPS (x)	44.1	30.3	24.2	16.3	15.2
EV/EBITDA (x)	32.96	24.29	24.98	14.28	1.04
Dividend Payout (%)	45.6	27.0	20.0	20.0	20.0
m cap/sales (x)	7.5	5.6	5.0	3.5	3.2
net debt/equity (x)	0.1	0.2	1.1	0.5	0.2
net debt/ebitda (x)	0.1	0.4	2.7	1.0	0.0

ource. company rinings, matanivesir researc

**Torrent Pharmaceuticals Ltd.** 

Disclaimer: This document has been prepared by IndiaNivesh Securities Private Limited ("INSPL"), for use by the recipient as information only and is not for circulation or public distribution. INSPL includes subsidiaries, group and associate companies, promoters, employees and affiliates. INSPL researches, aggregates and faithfully reproduces information available in public domain and other sources, considered to be reliable and makes them available for the recipient, though its accuracy or completeness has not been verified by INSPL independently udgement with regard to such content. This document has been published in accordance with the provisions of Regulation 18 of the Securities and Exchange Board of India (Research Analysts) Regulations, 2014. This document is not to be altered, transmitted, reproduced, copied, redistributed, uploaded or published or made available to others, in any form, in whole or in part, for any purpose without prior written permission from INSPL. This document is solely for information purpose and should not to be construed as an offer to sell or the solicitation of an offer to buy any security. Recipients of this document should be aware that past performance is not necessarily a guide for future performance and price and value of investments cang ou por down. The suitability or otherwise of any investments will depend upon the recipients particular circumstances. INSPL does not take responsibility thereof. The research analysts of INSPL have adhered to the code of conduct under Regulation 24 (2) of the Securities and Exchange Board of India (Research Analysts) Regulations, 2014. This document is assuch, may not match with a report on a company's fundamentals and, as such, may not match with a report on a company's fundamentals. Nothing in this document constitutes investment, legal, accounting and/or tax advice or a representation that any investment or strategy is suitable or for any omission or for any lability arising from the use of this document. Opinions expressed are our c

This report is based / focused on fundamentals of the Company and forward-looking statements as such, may not match with a report on a company's technical analysis report

Each of the analysts named below hereby certifies that, with respect to each subject company and its securities for which the analyst is responsible in this report, (1) all of the views expressed in this report accurately reflect his or her personal views about the subject companies and securities, and (2) no part of his or her compensation was, is, or will be, directly or indirectly, related to the specific recommendations or views expressed in this report: Daljeet S Kohli, Amar Maurya, Abhishek Jain, Yogesh Hotwani, Prerna Jhunjhunwala, Kaushal Patel, Rahul Koli, Tushar Manudhane & Dharmesh Kant.

Following table contains the disclosure of interest in order to adhere to utmost transparency in the matter:
Disclosure of Interest Statement

	Disclosure of Interest Statement					
1.	Details of business activity of IndiaNivesh Securities Private Limited (INSPL)	INSPL is a Stock Broker registered with BSE, NSE and MCX - SX in all the major segments viz. Cash, F & O and CDS segments. INSPL is also a Depository Participant and registered with both Depository viz. CDSL and NSDL. Further, INSPL is a Registered Portfolio Manager and is registered with SEBI.				
2.	Details of Disciplinary History of INSPL	No disciplinary action is / was running / initiated against INSPL				
3.	Details of Associates of INSPL	Please refer to the important 'Stock Holding Disclosure' report on the IndiaNivesh website (investment Research Section - <u>http://www.indianivesh.in/Research/Holding_Disclosure.aspx?id=10</u> link). Also, please refer to the latest update on respective stocks for the disclosure status in respect of those stocks. INSPL and its affiliates may have investment positions in the stocks recommended in this report.				
4.	Research analyst or INSPL or its relatives'/associates' financial interest in the subject company and nature of such financial interest	No (except to the extent of shares held by Research analyst or INSPL or its relatives/associates')				
5.	Research analyst or INSPL or its relatives'/associates' actual/beneficial ownership of 1% or more in securities of the subject company, at the end of the month immediately preceding the date of publication of the document.	Please refer to the important 'Stock Holding Disclosure' report on the IndiaNivesh website (investment Research Section - <u>http://www.indianivesh.in/Research/Holding_Disclosure.aspx?id=10</u> link). Also, please refer to the latest update on respective stocks for the disclosure status in respect of those stocks. INSPL and its affiliates may have investment positions in the stocks recommended in this report.				
6.	Research analyst or INSPL or its relatives'/associates' any other material conflict of interest at the time of publication of the document	No				
7.	Has research analyst or INSPL or its associates received any compensation from the subject company in the past 12 months	No				
8.	Has research analyst or INSPL or its associates managed or co-managed public offering of securities for the subject company in the past 12 months	No				
9.	Has research analyst or INSPL or its associates received any compensation for investment banking or merchant banking or brokerage services from the subject company in the past 12 months	No				
10.	Has research analyst or INSPL or its associates received any compensation for products or services other than investment banking or merchant banking or brokerage services from the subject company in the past 12 months	No				
11.	Has research analyst or INSPL or its associates received any compensation or other benefits from the subject company or third party in connection with the document.	No				
12.	Has research analyst served as an officer, director or employee of the subject company	No				
13.	Has research analyst or INSPL engaged in market making activity for the subject company	No				
14.	Other disclosures	No				
	its offiliated directors, its propriatory trading and investment hypinasses may from time to time	, make investment decisions that are inconsistent with an contradictory to the recommon detions overcosed				

INSPL, its affiliates, directors, its proprietary trading and investment businesses may, from time to time, make investment decisions that are inconsistent with or contradictory to the recommendations expressed herein. The views contained in this document are those of the analyst, and the company may or may not subscribe to all the views expressed within. This information is subject to change, as per applicable law, without any prior notice. INSPL reserves the right to make modifications and alternations to this statement, as may be required, from time to time.

#### Definitions of ratings

BUY. We expect this stock to deliver more than 15% returns over the next 12 months.

HOLD. We expect this stock to deliver -15% to +15% returns over the next 12 months.

SELL. We expect this stock to deliver <-15% returns over the next 12 months.

Our target prices are on a 12-month horizon basis.

#### Other definitions

NR = Not Rated. The investment rating and target price, if any, have been arrived at due to certain circumstances not in control of INSPL

CS = Coverage Suspended. INSPL has suspended coverage of this company.

UR=Under Review. Such e invest review happens when any developments have already occurred or likely to occur in target company & INSPL analyst is waiting for some more information to draw conclusion on rating/target.

NA = Not Available or Not Applicable. The information is not available for display or is not applicable

NM = Not Meaningful. The information is not meaningful and is therefore excluded.

Research Analyst has not served as an officer, director or employee of Subject Company

One year Price history of the daily closing price of the securities covered in this note is available at <u>www.nseindia.com</u> and <u>www.economictimes.indiatimes.com/markets/stocks/stock-quotes</u>. (Choose name of company in the list browse companies and select 1 year in icon YTD in the price chart)



#### IndiaNivesh Securities Private Limited

Research Analyst SEBI Registration No. INH000000511

601 & 602, Sukh Sagar, N. S. Patkar Marg, Girgaum Chowpatty, Mumbai 400 007.

Tel: (022) 66188800 / Fax: (022) 66188899

e-mail: research@indianivesh.in | Website: www.indianivesh.in

IndiaNivesh Research

#### **Torrent Pharmaceuticals Ltd.**

June 26, 2015| 3

Home

IndiaNivesh Research is also available on Bloomberg INNS, Thomson First Call, Reuters and Factiva INDNIV.